Effect of edaravone dexborneol treatment on Trx，NLR and neurological function in patients with acute ischemic stroke

doi:10.3877/cma.j.issn.2095-123X.2024.06.007

Abstract

Abstract:

Objective

To investigate the effects of edaravone dexborneol treatment on thioredoxin（Trx），neutrophil-to-lymphocyte ratio （NLR） and neurological function in patients with acute ischemic stroke （AIS）.

Methods

One hundred and twenty AIS patients who received treatment in the Neurology Department of Jurong People's Hospital from January 2022 to December 2023 were divided into the experimental group （60 cases） and the control group （60 cases） through the random number table method.The control group was given conventional treatment，and the experimental group was treated with edaravone dexborneol in addition to conventional treatment，with a treatment duration of 14 d for both groups. The National Institutes of Health stroke scale （NIHSS） was used to assess the degree of neurological deficit in patients. The Trx levels，NLR levels，NIHSS scores before and after 14 d of treatment，and incidence of adverse reactions during treatment were compared between two groups of patients.

Results

There was no statistically significant difference in Trx levels，NLR levels，and NIHSS scores between the two groups of patients before treatment （P＞0.05）. Compared with before treatment，the Trx levels，NLR levels，and NIHSS scores of both groups of patients decreased after treatment，and the experimental group was lower than the control group，with statistically significant differences （P＜0.05）.The total effective rate of the experimental group （96.67%） was higher than that of the control group（83.33%），and the difference was statistically significant （P＜0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients （P＞0.05）.

Conclusion

Edaravone dexborneol can significantly reduce the level of Trx and NLR in AIS patients，improve neurological function，and do not increase adverse reactions.

Key words: Acute ischemic stroke, Edaravone dexborneol, Thioredoxin, Neutrophil-tolymphocyte ratio, Neurological function

Yi Wang, Lu Xu. Effect of edaravone dexborneol treatment on Trx，NLR and neurological function in patients with acute ischemic stroke[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2024, 14(06): 359-364.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2024.06.007

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2024/V14/I06/359

Figures/Tables 4

References 28

[1]	胡飞龙，路璐.胞磷胆碱对大脑中动脉缺血性脑卒中恢复期的疗效[J]. 中华脑科疾病与康复杂志（电子版），2023，13（1）：51-56.DOI：10.3877/cma.j.issn.2095-123X.2023.01.006.Hu FL，Lu L. Effect of citicoline on the recovery period of middle cerebral artery ischemic stroke[J]. Chin J Brain Dis Rehabil（Electronic Edition），2023，13（1）：51-56.DOI：10.3877/cma.j.issn.2095-123X.2023.01.006.
[2]	尚慧娟，袁晓冬.机械取栓术后应用依达拉奉右崁醇对急性缺血性脑卒中预后的改善[J]. 中华神经创伤外科电子杂志，2023，9（5）：295-301. DOI：10.3877/cma.j.issn.2095-9141.2023.05.007.Shang HJ，Yuan XD. Improvement of prognosis of acute cerebral ischemic stroke with edaravone dexborneol after mechanical thrombectomy[J]. Chin J Neurotrauma Surg （Electronic Edition），2023，9（5）：295-301. DOI：10.3877/cma.j.issn.2095-9141.2023.05.007.
[3]	Herpich F，Rincon F. Management of acute ischemic stroke[J].Crit Care Med，2020，48（11）：1654-1663. DOI：10.1097/CCM.00 00000000004597.
[4]	Jenny NS，Callas PW，Judd SE，et al. Inflammatory cytokines and ischemic stroke risk：the REGARDS cohort[J]. Neurology，2019，92（20）：e2375-e2384.DOI：10.1212/WNL.0000000000007416.
[5]	Chamorro Á，Lo EH，Renú A，et al. The future of neuroprotection in stroke[J].J Neurol Neurosurg Psychiatry，2021，92（2）：129-135.DOI：10.1136/jnnp-2020-324283.
[6]	Cao Y，Yue X，Jia M，et al. Neuroinflammation and anti -inflammatory therapy for ischemic stroke[J]. Heliyon，2023，9（7）：e17986.DOI：10.1016/j.heliyon.2023.e17986.
[7]	中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9）：666-682.DOI：10.3760/cma.j.issn.1006-7876.2018.09.004.Chinese Society of Neurology； Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Chin J Neurol，2018，51（9）：666-682. DOI：10.3760/cma.j.issn.1006-7876.2018.09.004.
[8]	Yoshimura S，Sakai N，Yamagami H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.DOI：10.1056/NEJMoa2118191.
[9]	辜忠灵，丁秀英，甘秀红，等.低频重复经颅电刺激联合依达拉奉治疗急性脑梗死的临床疗效观察[J]. 实用医院临床杂志，2023，20（5）：95-98.DOI：10.3969/j.issn.1672-6170.2023.05.023.Gu ZL，Ding XY，Gan XH，et al. Clinical efficacy observation of low frequency repetitive transcranial electrical stimulation combined with edaravone in the treatment of acute cerebral infarction[J].Practical J Clin Med，2023，20（5）：95-98. DOI：10. 3969/j.issn.1672-6170.2023.05.023.
[10]	Xi Y，Ma J，Lu S.Favorable neuroprotective effect of intra-arterial application of edaravone dexborneol in ischemic stroke rats[J]. J Stroke Cerebrovasc Dis，2023，32（11）：107356. DOI：10.1016/j.jstrokecerebrovasdis.2023.107356.
[11]	Wang L，Liang Q，Lin A，et al. Borneol alleviates brain injury in sepsis mice by blocking neuronal effect of endotoxin[J]. Life Sci，2019，232：116647.DOI：10.1016/j.lfs.2019.116647.
[12]	Li L，He G，Shi M，et al. Edaravone dexborneol ameliorates cognitive impairment by regulating the NF-κB pathway through AHR and promoting microglial polarization towards the M2 phenotype in mice with bilateral carotid artery stenosis （BCAS）[J].Eur J Pharmacol，2023，957：176036.DOI：10.1016/j.ejphar.2023.176036.
[13]	Wu HY，Tang Y，Gao LY，et al.The synergetic effect of edaravone and borneol in the rat model of ischemic stroke[J]. Eur J Pharmacol，2014，740：522-531.DOI：10.1016/j.ejphar.2014.06.035.
[14]	王倩倩，刘斌，郭娟.依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的疗效与安全性观察[J]. 中风与神经疾病杂志，2022，39（4）：333-335.DOI：10.19845/j.cnki.zfysjjbzz.2022.0084.Wang QQ，Liu B，Guo J. Efficacy and safety of edaravone dexborneol in the treatment of acute cerebral infarction[J]. J Apoplexy Nerv Dis，2022，39（4）：333-335. DOI：10.19845/j.cnki.zfysjjbzz.2022.0084.
[15]	Muri J，Kopf M. Redox regulation of immunometabolism[J]. Nat Rev Immunol，2021，21（6）：363-381. DOI：10.1038/s41577-020-00478-8.
[16]	Yu T，Zhang W，Lin Y，et al. Prognostic value of serum thioredoxin levels in ischemic stroke[J].Neurol Res，2017，39（11）：988-995.DOI：10.1080/01616412.2017.1359882.
[17]	Wu MH，Song FY，Wei LP，et al. Serum levels of thioredoxin are associated with stroke risk，severity，and lesion volumes[J]. Mol Neurobiol，2016，53（1）：677-685.DOI：10.1007/s12035-014-9016-y.
[18]	Yarana C，Thompson H，Chaiswing L，et al. Extracellular vesiclemediated macrophage activation：an insight into the mechanism of thioredoxin-mediated immune activation[J]. Redox Biol，2019，26：101237.DOI：10.1016/j.redox.2019.101237.
[19]	Sivandzade F，Prasad S，Bhalerao A，et al. NRF2 and NF-κB interplay in cerebrovascular and neurodegenerative disorders：molecular mechanisms and possible therapeutic approaches[J].Redox Biol，2019，21：101059.DOI：10.1016/j.redox.2018.11.017.
[20]	Zhang YX，Shen ZY，Jia YC，et al. The association of the neutrophil-to-lymphocyte ratio，platelet-to-lymphocyte ratio，lymphocyte - to - monocyte ratio and systemic inflammation response index with short-term functional outcome in patients with acute ischemic stroke[J]. J Inflamm Res，2023，16：3619-3630.DOI：10.2147/JIR.S418106.
[21]	Lux D，Alakbarzade V，Bridge L，et al. The association of neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio with 3-month clinical outcome after mechanical thrombectomy following stroke[J]. J Neuroinflammation，2020，17（1）：60. DOI：10.1186/s12974-020-01739-y.
[22]	Szepanowski RD，Haupeltshofer S，Vonhof SE，et al.Thromboinflammatory challenges in stroke pathophysiology[J].Semin Immunopathol，2023，45（3）：389-410. DOI：10.1007/s00281-023-00994-4.
[23]	Liu H，Liu K，Zhang K，et al. Early neurological deterioration in patients with acute ischemic stroke：a prospective multicenter cohort study[J]. Ther Adv Neurol Disord，2023，16：17562864 221147743.DOI：10.1177/17562864221147743.
[24]	Gong P，Liu Y，Gong Y，et al. The association of neutrophil to lymphocyte ratio，platelet to lymphocyte ratio，and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke[J]. J Neuroinflammation，2021，18（1）：51.DOI：10.1186/s12974-021-02090-6.
[25]	Massiot N，Lareyre F，Voury-Pons A，et al. High neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with symptomatic internal carotid artery stenosis[J]. J Stroke Cerebrovasc Dis，2019，28（1）：76-83. DOI：10.1016/j.jstrokecerebrovasdis.2018.09.001.
[26]	Giede-Jeppe A，Madžar D，Sembill JA，et al.Increased neutrophilto - lymphocyte ratio is associated with unfavorable functional outcome in acute ischemic stroke[J]. Neurocrit Care，2020，33（1）：97-104.DOI：10.1007/s12028-019-00859-5.
[27]	Sharma D，Spring KJ，Bhaskar SMM. Neutrophil-lymphocyte ratio in acute ischemic stroke：immunopathology，management，and prognosis[J].Acta Neurol Scand，2021，144（5）：486-499.DOI：10.1111/ane.13493.
[28]	Wang L，Song Q，Wang C，et al. Neutrophil to lymphocyte ratio predicts poor outcomes after acute ischemic stroke：a cohort study and systematic review[J].J Neurol Sci，2019，406：116445.DOI：10.1016/j.jns.2019.116445.

项目	试验组（n=60）	对照组（n=60）	t/χ²/Z值	P值
年龄（岁，Mean±SD）	61.45±6.09	61.22±9.95	0.155	0.877
男性[例（%）]	34（56.67）	31（51.67）	0.302	0.583
吸烟[例（%）]	20（33.33）	18（30.00）	0.154	0.695
饮酒[例（%）]	19（31.67）	18（30.00）	0.039	0.843
高血压[例（%）]	31（51.67）	35（58.33）	0.539	0.463
糖尿病[例（%）]	21（35.00）	18（30.00）	0.342	0.559
冠心病[例（%）]	7（11.67）	8（13.33）	0.076	0.783
FBG[mmol/L，M（P₂₅，P₇₅）]	5.10（4.61，5.87）	4.90（4.35，5.80）	-1.526	0.127
TG[mmol/L，M（P₂₅，P₇₅）]	1.24（0.78，1.80）	1.35（0.98，2.01）	-1.845	0.065
TC[mmol/L，M（P₂₅，P₇₅）]	3.95（3.45，4.52）	3.82（3.47，4.60）	-1.244	0.213
HDL[mmol/L，M（P₂₅，P₇₅）]	1.21（1.01，1.57）	1.30（1.18，1.71）	-1.772	0.076
LDL[mmol/L，M（P₂₅，P₇₅）]	2.09（1.77，2.78）	2.24（1.78，2.48）	-1.307	0.191

项目	试验组（n=60）	对照组（n=60）	t/χ²/Z值	P值
年龄（岁，Mean±SD）	61.45±6.09	61.22±9.95	0.155	0.877
男性[例（%）]	34（56.67）	31（51.67）	0.302	0.583
吸烟[例（%）]	20（33.33）	18（30.00）	0.154	0.695
饮酒[例（%）]	19（31.67）	18（30.00）	0.039	0.843
高血压[例（%）]	31（51.67）	35（58.33）	0.539	0.463
糖尿病[例（%）]	21（35.00）	18（30.00）	0.342	0.559
冠心病[例（%）]	7（11.67）	8（13.33）	0.076	0.783
FBG[mmol/L，M（P₂₅，P₇₅）]	5.10（4.61，5.87）	4.90（4.35，5.80）	-1.526	0.127
TG[mmol/L，M（P₂₅，P₇₅）]	1.24（0.78，1.80）	1.35（0.98，2.01）	-1.845	0.065
TC[mmol/L，M（P₂₅，P₇₅）]	3.95（3.45，4.52）	3.82（3.47，4.60）	-1.244	0.213
HDL[mmol/L，M（P₂₅，P₇₅）]	1.21（1.01，1.57）	1.30（1.18，1.71）	-1.772	0.076
LDL[mmol/L，M（P₂₅，P₇₅）]	2.09（1.77，2.78）	2.24（1.78，2.48）	-1.307	0.191

组别	例数	Trx（ng/L）				NLR
组别	例数	治疗前	治疗14 d	t值	P值	治疗前	治疗14 d	t值	P值
试验组	60	692.93±93.83	467.88±88.71	13.500	＜0.001	4.24±0.91	2.63±0.78	10.373	＜0.001
对照组	60	686.99±84.76	516.38±84.43	-11.046	＜0.001	4.48±0.88	3.46±0.92	-6.228	＜0.001
t值		0.364	-3.067			-1.512	-5.311
P值		0.716	0.003			0.133	＜0.001

组别	例数	Trx（ng/L）				NLR
组别	例数	治疗前	治疗14 d	t值	P值	治疗前	治疗14 d	t值	P值
试验组	60	692.93±93.83	467.88±88.71	13.500	＜0.001	4.24±0.91	2.63±0.78	10.373	＜0.001
对照组	60	686.99±84.76	516.38±84.43	-11.046	＜0.001	4.48±0.88	3.46±0.92	-6.228	＜0.001
t值		0.364	-3.067			-1.512	-5.311
P值		0.716	0.003			0.133	＜0.001

组别	例数	治疗前	治疗14 d	t值	P值
试验组	60	7.37±1.63	4.37±1.70	9.888	＜0.001
对照组	60	7.20±1.69	5.28±1.93	5.719	＜0.001
t值		0.551	-2.761
P值		0.582	0.007

Please choose a citation manager

Content to export